Proactive Investors Interview – Algernon Pharmaceuticals Releases Details of Planned Phase 2b Chronic Cough Study of Ifenprodil
Proactive Investors Interview – Algernon Pharmaceuticals Releases Details of Planned
Phase 2b Chronic Cough Study of Ifenprodil
Algernon Pharmaceuticals CEO Christopher J. Moreau joined Steve Darling from Proactive to share news the Company has announced it is planning a 180 patient, 3-month Phase 2b clinical study of Ifenprodil for chronic cough.
Mr. Moreau explains that the study is set to begin in Q3 of 2023 and is being done after the Company’s encouraging Phase 2a study results and positive feedback received from the U.S. FDA at its pre-investigational New Drug (pre-IND) meeting.
